Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers. Now, researchers working in the U.S., Germany and China have shown how chemotherapy drugs called thiopurines can lead to mutations that set patients up for relapse. The work appears today in the journal Nature Cancer.
The research provides the first direct genomic and experimental evidence in pediatric cancer that drug-resistant mutations can be induced by chemotherapy and are not always present at diagnosis.
“The findings offer a paradigm shift in understanding how drug resistance develops,” said Jinghui Zhang, Ph.D., Department of Computational Biology chair at St. Jude Children’s Research Hospital. “The results also suggest possible treatment strategies for ALL patients who relapse, including screening to identify those who should avoid additional thiopurine treatment.”
Zhang is co-corresponding author of the study with Bin-Bing Zhou, Ph.D., of Shanghai Children’s Medical Center; and Renate Kirschner-Schwabe, M.D., of Charite-Universitaetsmedizin Berlin.
The roots of relapse
While 94% of St. Jude patients with ALL become five-year survivors, relapse remains the leading cause of death worldwide for children and adolescents with ALL.
This study involved ALL samples collected from relapsed pediatric ALL patients in the U.S., China and Germany. Researchers analyzed more than 1,000 samples collected from the patients at different times in treatment, including samples from 181 patients collected at diagnosis, remission and relapse.
Co-first author Samuel Brady, Ph.D., of St. Jude Computational Biology, identified a mutational signature that helped decipher the process. Mutational signatures reflect the history of genetic changes in cells.
Brady and his colleagues linked increased thiopurine-induced mutations to genes such as MSH2 that become mutated in leukemia. The mutations inactivated a DNA repair process called mismatch repair and rendered ALL resistant to thiopurines. The combination fueled a 10-fold increase in ALL mutations, including an alteration in the tumor suppressor gene TP53. The mutation, TP53 R248Q, promoted resistance to multiple chemotherapy drugs, including vincristine, daunorubicin and cytarabine.
Working in two cell lines in the laboratory, Zhou and his colleagues replicated the thiopurine-induced TP53 mutations and chemotherapy resistance. The research provided the first direct genomic and experimental evidence of chemotherapy-induced drug resistance mutations. “This study not only changes our ALL treatment considerations, but also opens the door to study mechanistically how defective repair generates drug-resistant mutations,” Zhou said.
Chemotherapy’s role in relapse
Researchers estimate that treatment-induced mutations play a role in 25% of pediatric ALL relapse. Eight percent of patients in this study had evidence of the thiopurine-associated mismatch-repair signature.
“In the future, it may be possible to monitor bone marrow during treatment as a way to detect these mutational signatures early enough to help identify at-risk patients who may be candidates for emerging therapies like CAR-T cells,” Zhang said. But the researchers stressed that the benefits of thiopurine treatment outweigh the risks, noting that most patients are unaffected by thiopurine-induced mutations.
Authors and funding
The other first authors are Fan Yang, Chao Tang, Huiying Sun and Lijuan Du, all of Shanghai Jiao Tong University School of Medicine. The other authors are Malwine Barz, Arend von Stackelberg and Cornelia Eckert of Charite-Universitaetsmedizin; Yao Chen, Houshun Fang, Xiaomeng Li, Jiaoyang Cai, Lixia Ding, Tianyi Wang, Shuhong Shen, Hongzhuan Chen, Caiwen Duan, Yu Liu, Hui Li and Benshang Li of Shanghai Jiao Tong University School of Medicine; and Xiaotu Ma, Pandurang Kolekar, Omkar Pathak, and Jeffery Klco of St. Jude.
The research was funded in part by the National Natural Science Foundation of China; National Key R&D Program of China; Shanghai Rising-Star Program; German Childhood Cancer Foundation and ALSAC, the St. Jude fundraising and awareness organization.
Yang, F., et al. (2021) Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. Nature Cancer. doi.org/10.1038/s43018-021-00230-8.